Deep Track Capital, LP
Q3 2022 13F-HR Holdings
Net value change ($000)
+662,317
(43.5%)
New positions
16
Sold out positions
5
Turnover %
33.9%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2022
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| Horizon Therapeutics Public Ltd Co | 90,533 | NEW |
| ASND | 82,608 | NEW |
| IVERIC bio, Inc. | 82,290 | 190.1% |
| SpringWorks Therapeutics, Inc. | 67,594 | NEW |
| AUPH | 42,694 | NEW |
| JAZZ | 36,758 | 47.1% |
| HRTX | 36,074 | NEW |
| EWTX | 33,204 | NEW |
| PLRX | 29,241 | NEW |
| VRNA | 28,913 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| Global Blood Therapeutics, Inc. | -94,271 | -80.9% |
| MDGL | -64,780 | -100.0% |
| ACAD | -24,420 | -100.0% |
| KURA | -24,262 | -35.8% |
| FATE | -20,624 | -41.2% |
| NUVB | -16,278 | -43.8% |
| Tricida, Inc. | -14,105 | -53.3% |
| KROS | -11,084 | -54.2% |
| SDGR | -10,595 | -71.4% |
| Forma Therapeutics Holdings, Inc. | -8,622 | -30.9% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
159,538
(7.3% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|